CytoSorbents Corp is a critical care immunotherapy company. It investigates and commercializes its blood purification technology to reduce uncontrolled inflammation in hospitalized patients internationally with the goal of preventing and treating multiple organ failure in life-threatening illnesses and cardiac surgery. Its product portfolio consists of Cytosord, Contrastsorb, Vetresq, Hemodefend and Drugsorb. The company's intellectual property consists of composition of matter, materials, methods of production, systems incorporating the technology and multiple medical uses. It derives its revenue from product sales and grants.
| Website: | www.cytosorbents.com |
| Email: | avogel@cytosorbents.com |
| Main Phone: | +1 732 329-8885 |
| Address: | 7 Deer Park Drive |
| Address 2: | Suite K |
| State: | NJ |
| City / Town: | Monmouth Junction |
| Country: | USA |
| Postal Code: | 08852 |
| Exchange: | NSC |
| CEO: | Phillip P. Chan |
| Employees: | 117 |
| NAICS: | Medical Laboratories(621511) |
| Last Price 8.86 | Change $ -0.06 | Change % -0.67 | Tick N/A |
| Bid 8.36 | Bid Size 500.00 | Ask 11.00 | Ask Size 300.00 |
| Open 9.05 | High 9.05 | Low 8.67 | Prev Close 8.92 |
| Last Trade | Volume 167,100 | 52 Wk Hi 14.95 | 52 Wk Low 5.95 |
| Market Cap 280.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 31,651,821.00 | EPS (TTM) -0.50 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 26 | 55 |
| Number of Buys | 13 | 33 |
| Number of Sells | 13 | 22 |
| Net Activity | 24785 | 225628 |
| Last 10 Buys | Shares |
|---|---|
| Michael G. Bator | 1,000 |
| Eric R. Mortensen | 1,000 |
| Phillip P. Chan | 1,000 |
| Edward R. Jones | 1,000 |
| Edward R. Jones | 1,000 |
| Vincent Capponi | 1,000 |
| Phillip P. Chan | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Phillip P. Chan | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 14 | 14 | 14 | 14 |
| Low Target Price Estimate | 11 | 11 | 11 | 11 |
| Mean Target Price Estimate | 12.6 | 12.6 | 12.6 | 12.6 |
| Standard Deviation | 1.14 | 1.14 | 1.14 | 1.14 |
| Date of Most Recent Estimate | 05/23/18 | 05/23/18 | 05/23/18 | 05/23/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-24 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 73 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
